ISO 27001 vs FDA 21 CFR Part 11
ISO 27001
International standard for information security management systems
FDA 21 CFR Part 11
FDA regulation for electronic records and signatures equivalence.
Quick Verdict
ISO 27001 provides voluntary ISMS certification for global security resilience, while FDA 21 CFR Part 11 mandates controls for trustworthy electronic records/signatures in US life sciences. Companies adopt ISO for broad compliance, Part 11 for regulatory necessity.
ISO 27001
ISO/IEC 27001:2022
Key Features
- Risk-based approach to ISMS implementation
- PDCA cycle for continual improvement
- 93 Annex A controls in four themes
- Technology-agnostic and industry-scalable framework
- Internationally recognized certification standard
FDA 21 CFR Part 11
21 CFR Part 11 Electronic Records; Electronic Signatures
Key Features
- Secure audit trails for all record changes
- Closed and open system controls
- Electronic signature linking and manifestation
- Risk-based system validation requirements
- Access, authority, and device checks
Detailed Analysis
A comprehensive look at the specific requirements, scope, and impact of each standard.
ISO 27001 Details
What It Is
ISO/IEC 27001:2022 is the international certification standard for establishing, implementing, maintaining, and improving an Information Security Management System (ISMS). It provides a systematic, risk-based framework to manage information risks across confidentiality, integrity, and availability, applicable to all organization sizes and industries.
Key Components
- Mandatory Clauses 4-10 cover context, leadership, planning, support, operation, evaluation, and improvement.
- Annex A includes 93 controls grouped into organizational (37), people (8), physical (14), and technological (34) themes.
- Built on PDCA cycle for continual improvement.
- Optional certification via accredited auditors with Stage 1/2 audits, surveillance, and recertification.
Why Organizations Use It
- Enhances resilience against breaches, reduces incident costs (avg. over $5M).
- Meets regulatory/contractual needs (e.g., GDPR, NIS2); voluntary but often required for tenders.
- Drives competitive edges like 20-30% more bids won, insurance discounts.
- Builds stakeholder trust via independent certification.
Implementation Overview
Phased approach: initiation, risk assessment, control deployment, audits (6-18 months). Scalable for SMEs/enterprises; requires leadership, training, documentation.
FDA 21 CFR Part 11 Details
What It Is
FDA 21 CFR Part 11 is a U.S. federal regulation establishing criteria for electronic records and electronic signatures to be considered trustworthy, reliable, and equivalent to paper records and handwritten signatures. It applies to FDA-regulated industries using electronic systems for predicate-rule-required records. The approach is risk-based, with narrow scope per 2003 FDA guidance, enforcing core controls while exercising discretion on some elements.
Key Components
- Subparts: General provisions, electronic records (closed/open systems), electronic signatures.
- Core controls: validation (§11.10(a)), audit trails (§11.10(e)), access limits (§11.10(d)), operational/authority/device checks (§11.10(f)-(h)), training (§11.10(i)), signature linking (§11.70).
- Built on ALCOA+ principles for data integrity; no formal certification, but inspection readiness required.
Why Organizations Use It
- Mandatory for electronic reliance in pharma, devices, biologics to avoid enforcement.
- Enhances data integrity, supports inspections, reduces recalls.
- Builds trust, enables digital transformation, aligns with global standards like EU Annex 11.
Implementation Overview
- Phased: scoping, gap analysis, validation (IQ/OQ/PQ), SOPs, training.
- Applies to life sciences firms using electronic records; risk-based for all sizes.
Key Differences
| Aspect | ISO 27001 | FDA 21 CFR Part 11 |
|---|---|---|
| Scope | Information Security Management System across all assets | Electronic records and signatures for FDA predicate rules |
| Industry | All industries worldwide, any size | Life sciences, pharma, devices, US-regulated |
| Nature | Voluntary international certification standard | Mandatory US FDA regulation with enforcement |
| Testing | Risk-based internal audits, certification audits | System validation (IQ/OQ/PQ), FDA inspections |
| Penalties | Loss of certification, no legal fines | Warning letters, fines, product holds, seizures |
Scope
Industry
Nature
Testing
Penalties
Frequently Asked Questions
Common questions about ISO 27001 and FDA 21 CFR Part 11
ISO 27001 FAQ
FDA 21 CFR Part 11 FAQ
You Might also be Interested in These Articles...
The Panoramic View: How Integrated Compliance Monitoring Creates Unprecedented Organizational Visibility and Adaptability
Gain unprecedented organizational visibility with integrated compliance monitoring. Automate real-time alerts, ensure GDPR & SOC 2 adherence, reduce risks, and
Top 10 SOC 2 Audit Pitfalls and Fixes: Real Auditor Red Flags from Type 2 Fieldwork with Evidence Checklists
Discover 10 common SOC 2 Type 2 audit pitfalls like evidence gaps, scope creep, vendor oversights. Get Fail/Pass visuals, client stories, checklists for 95% fir
NIST CSF 2.0 Plain English Decoder: Translating Govern, Supply Chain, and Core Functions from Jargon to Actionable Insights
Demystify NIST CSF 2.0 jargon with plain English tables for Govern, Supply Chain & Core Functions. Actionable steps for risk oversight & vendor management. Empo
Run Maturity Assessments with GRADUM
Transform your compliance journey with our AI-powered assessment platform
Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.
Explore More Comparisons
See how ISO 27001 and FDA 21 CFR Part 11 compare against other standards